Last reviewed · How we verify

Tramadol HCl

Labopharm Inc. · FDA-approved active Small molecule Under review Quality 0/100

Tramadol HCl is a Synthetic opioid analgesic with monoamine reuptake inhibition Small molecule drug developed by Labopharm Inc.. It is currently FDA-approved for Moderate pain in adults, Moderate to moderately severe pain. Also known as: RWJ-26898-002, Ultram, Ultram ER, Drug A.

Tramadol is a synthetic opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief.

Tramadol HCl is a small molecule that acts as a mu opioid receptor agonist, classified as an agonist. It is used to treat various types of pain, including moderate to severe pain, postoperative pain, and osteoarthritis pain, among others.

At a glance

Generic nameTramadol HCl
Also known asRWJ-26898-002, Ultram, Ultram ER, Drug A, tramadol hydrochloride
SponsorLabopharm Inc.
Drug classSynthetic opioid analgesic with monoamine reuptake inhibition
TargetMu opioid receptor; norepinephrine transporter; serotonin transporter
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Tramadol works through dual mechanisms: it acts as a weak mu opioid receptor agonist and simultaneously inhibits the reuptake of norepinephrine and serotonin in the central nervous system. This combination of opioid and monoamine reuptake inhibition provides analgesic effects for moderate pain. The norepinephrine and serotonin reuptake inhibition contributes significantly to its pain-relieving properties, making it effective at lower opioid doses than traditional opioids.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tramadol HCl

What is Tramadol HCl?

Tramadol HCl is a Synthetic opioid analgesic with monoamine reuptake inhibition drug developed by Labopharm Inc., indicated for Moderate pain in adults, Moderate to moderately severe pain.

How does Tramadol HCl work?

Tramadol is a synthetic opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief.

What is Tramadol HCl used for?

Tramadol HCl is indicated for Moderate pain in adults, Moderate to moderately severe pain.

Who makes Tramadol HCl?

Tramadol HCl is developed and marketed by Labopharm Inc. (see full Labopharm Inc. pipeline at /company/labopharm-inc).

Is Tramadol HCl also known as anything else?

Tramadol HCl is also known as RWJ-26898-002, Ultram, Ultram ER, Drug A, tramadol hydrochloride.

What drug class is Tramadol HCl in?

Tramadol HCl belongs to the Synthetic opioid analgesic with monoamine reuptake inhibition class. See all Synthetic opioid analgesic with monoamine reuptake inhibition drugs at /class/synthetic-opioid-analgesic-with-monoamine-reuptake-inhibition.

What development phase is Tramadol HCl in?

Tramadol HCl is FDA-approved (marketed).

What are the side effects of Tramadol HCl?

Common side effects of Tramadol HCl include Dizziness, Nausea, Constipation, Headache, Somnolence, Vomiting.

What does Tramadol HCl target?

Tramadol HCl targets Mu opioid receptor; norepinephrine transporter; serotonin transporter and is a Synthetic opioid analgesic with monoamine reuptake inhibition.

Related